The combination is concerning economic data and a historically high valuation could spell trouble for the U.S. stock market.
Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback